Megan McKinney-Dyson was shocked when she received a diagnosis of stage 3b colon cancer in 2021. She was just 42 years old and the mother of two young boys. After undergoing surgery and six months of chemotherapy, she is now cancer-free.
However, the treatment left her with neuropathy, which, according to the American Cancer Society, is a condition that causes pain, numbness and tingling in the hands and feet.
Although her doctor warned her that neuropathy was a potential side effect of her treatment, she wasnt fully prepared for long-term pain and discomfort.
Neuropathy is the biggest thing that I still have to this day, McKinney-Dyson says. Its like constant pins and needles. Its very painful.
She tried medication, but it didnt provide the relief she was seeking. In addition, I didnt like the side effects of the medicine because it made me really tired, she says. So McKinneyDyson turned to alternative treatments such as occupational and physical therapy.
The gap in survivorship research means that patients such as McKinney-Dyson often have difficulty getting the care they need after finishing treatment.
Read more: Peripheral Neuropathy Is 'Underestimated' in Patients Undergoing Cancer Treatment
The growing numbers of cancer survivors are outstripping the capacity of cancer care systems to keep pace with demand, Dr. Aisha Ahmed, an oncologist at Arizona Oncology in Tucson, says.
Primary care physicians may not be adequately prepared to care for these survivors due to perceived knowledge gaps about the individualized needs, risks and surveillance plans for cancer survivors, Ahmed says. This is especially true for patients who are living with long-term side effects of their treatment.
Cancer treatment often involves powerful drugs that can damage the nerves, resulting in chemotherapy-induced peripheral neuropathy (CIPN). Although any type of cancer treatment can cause neuropathy, some drugs are more likely to cause the condition.
Certain types of chemotherapy drugs are neurotoxic, says Dr. Kord Kober, an associate professor of physiological nursing at the University of California, San Francisco. Unfortunately, two of the most common types of neurotoxic chemotherapies, platinum and taxane compounds, are used to treat some of the most common cancers breast, gastrointestinal, lung, gynecologic.
The condition can develop during treatment and persist long after treatment has ended. Due to the lack of prospective longitudinal studies that have evaluated the onset and persistence of CIPN, we do not know the recovery rates for CIPN, Kober says.
For McKinney-Dyson, the neuropathy affects the way she uses her hands and feet.
For the longest time I couldnt explain (the sensation), she says. She describes it as the worst feeling youve ever felt, for something you cant feel, meaning that she experiences the sensation of pain even though no physical stimuli are causing it.
McKinney-Dyson, who is an elementary school teacher, has had to adjust the way she does her job. Tying shoes, zipping jackets, buttoning clothes and even writing can be extremely painful. I have to take more frequent breaks when Im writing, she says. Typing is also difficult, and she often relies on her husbands help with many daily tasks.
CIPN is a relatively new field of study, and there is still much unknown about the condition. Kober works to increase awareness and understanding of CIPN to improve patient outcomes.
Results of a study he co-authored and is published in the Journal of Pain and Symptom Management, which focused on paclitaxelinduced peripheral neuropathy in cancer survivors, found that patients treated with paclitaxel chemotherapy had more problems with balance, the function of their upper extremities and more severe symptoms than patients who were not treated with the drug.
Results of the study also showed that those treated with paclitaxel had reduced quality of life scores in both physical and psychological domains.
Another study published in the Journal of Pain and Symptom Management found that body mass index may be a modifiable risk factor for the severity of chemotherapy-induced neuropathy. Research results show that survivors with a higher body mass index had more severe symptoms of neuropathy. This finding is significant because it suggests there may be ways to mitigate the severity of the condition with lifestyle and diet changes.
Mark Kantrowitz, a survivor of stage 3 testicular seminoma and author of Tumor Humor: Cancer Jokes and Anecdotes, has CIPN, even though it has been nearly two decades since his treatment ended.
After performing a self-exam at home in 2003 at the age of 36, Kantrowitz
found a lump on his testicle. His doctor scheduled an ultrasound for two weeks later, and the results confirmed that the mass was cancerous.
Kantrowitz began treatment immediately. He underwent orchiectomy surgery to remove his testicles and three cycles of chemotherapy and was treated with a combination of bleomycin, etoposide and cisplatin. He credits his research skills for helping him understand his diagnosis and treatment options throughout the process.
Aside from his longterm CIPN, Kantrowitz experienced many rare side effects and complications, including chemo-induced pancreatitis and gallstones, high-pitch hearing loss, Raynauds phenomenon (decreased blood flow in the fingers) and diabetes.
The neuropathy has caused him to experience numbness and tingling in his hands and feet, as well as muscle weakness. His symptoms are very noticeable when he walks, and he uses a cane to get around.
In my case, it mostly affected my feet, though occasionally it would affect the first three fingers on each hand, he says.
Its like wearing a pair of gloves on my feet, Kantrowitz says of the sensation. At the same time,there is a burning and tingling sensation, sometimes really severe. He describes the feeling as being similar to when the foot falls asleep and then begins to wake up. Multiply that by 10 and thats the sensation of neuropathy I experience, he says.
According to research published by the American Society of Clinical Oncology (ASCO), the effects of CIPN can last for years. Of 986 respondents to a 2020 ASCO survey, 77% reported current symptoms of CIPN, with the average respondent being more than three years post treatment.
McKinney-Dyson and Kantrowitz discovered ways to cope with their CIPN. McKinney-Dyson has made changes to her lifestyle and the way she completes everyday tasks. Although she didnt do well with the medication, six weeks of occupational and physical therapy helped her gain back some of the function shed lost.
For patients with cancer who are experiencing CIPN following treatment, there are some prescription medications that can be used to improve symptoms. One of them is duloxetine, Ahmed says. According to Kober, duloxetine is the only proven treatment for CIPN, but there are limited benefits to taking the medication.
Gabriela Miller, an oncology physiotherapist and owner of ACE Cancer Rehab in Mission, Kansas, works with cancer survivors before, during and after chemotherapy to help them manage treatment side effects such as neuropathy. She recommends patients with CIPN start by working with a physical therapist experienced in cancer-related side effects to help them regain function and strength as soon as possible.
CIPN is a very real and common side effect following chemotherapy that can have a huge impact on patients quality of life, Miller says. People who experience neuropathy have decreased sensation and circulation in their feet, which puts them at risk for falling or sustaining a soft tissue injury. If the foot is injured, they run the risk of not feeling the injury, which can potentially make the wound worse.
The effect that CIPN has on a patients life can be profound, with many risks and dangers that are often overlooked.
Another danger is increased risk of falling since the balance and sensation are impaired. We also see decreased muscle strength in the muscles of the toes, which further increases fall risk, Miller says.
Miller suggests patients with cancer consult with an oncology physical therapist as early as possible even before treatment starts. This way, we can detect and manage symptoms of neuropathy and educate the person on what to look for and how to improve their sensation and balance, she says.
She emphasizes that exercises to improve circulation and sensation, as well as balance training, are important components of therapy. Learning how to manage symptoms and risks prevent falls or other injuries associated with this neuropathy.
Kantrowitz, who did not take medication for his CIPN symptoms, found that there is no one-size-fits-all solution. Although he also has issues with daily tasks such as typing, he relies on proofreading software and spelling algorithms to help him. When asked what lifestyle changes have helped alleviate his symptoms, Kantrowitz says, Nothing really helps.
Despite that, having a positive attitude and high pain tolerance have boosted him through some of the darkest days.
Ive learned that I can work through the pain, he says. I have a constant burning sensation in my feet 24/7. He frequently uses distraction techniques to take his mind off the discomfort. Hes learned that his mind is a powerful tool for overcoming many obstacles, including neuropathy. If I dont focus on it, I can ignore it, he says.
Kantrowitz and McKinney-Dyson both agree that the lifesaving treatment was worth the side effects.
In my cancer joke book, Tumor Humor, I joke that its better to be alive with side effects than dead without, Kantrowitz says. I still would have had the same treatment. There really isnt anything I could have done differently.
There is much to learn about CIPN and scientists are working hard to find new ways to prevent and treat the side effect. Ahmed and Kober are hopeful that new medications and treatments will be developed to help those with this debilitating condition. Several ongoing clinical trials are testing new and advanced therapies.
In terms of pharmacology, there are numerous clinical trials under way to evaluate for drug therapeutics to prevent and treat CIPN, Kober says.
Scrambler therapy is one of the pain management techniques being studied. It uses electrical stimulation to scramble the pain signals being sent from the nerves to the brain. Although the study is still in the early phase, Ahmed is optimistic about the treatments potential.
Scrambler therapy is an emerging treatment approach that appears to benefit some affected patients with CIPN, she says. Small studies have suggested that scrambler therapy can reduce chemotherapy-induced neuropathy symptoms, even if symptoms have been present for more than one year.
Its a small ray of hope and something that patients such as McKinney-Dyson and Kantrowitz can hold on to. Kantrowitz recommends other survivors speak to their doctor about any side effects they may be experiencing, even years after treatment has ended.
For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.
Continue reading here:
Chemotherapy-Induced Peripheral Neuropathy: The Invisible Side Effect - Curetoday.com
- Peripheral neuropathy: Causes, symptoms, treatment, and prevention - September 21st, 2024
- Sponsored: Say goodbye to neuropathy with help from NexGenEsis Healthcare - KHOU.com - September 21st, 2024
- Danish Study Reveals Connection Between Diabetic Neuropathy, Retinopathy, and Severe Periodontitis - Medical Dialogues - September 21st, 2024
- What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And ... - Forbes - July 30th, 2024
- Neuropathy | Duke Health - October 16th, 2023
- Peripheral Neuropathy | University Hospitals - May 9th, 2023
- Cranial Neuropathies | University Hospitals - May 9th, 2023
- Treatment for Peripheral Neuropathy & Other Nerve Damage | University ... - May 9th, 2023
- Neuromuscular Disease | Facts About Neuromuscular Disorders, Symptoms ... - May 9th, 2023
- Patrick McIntyre MD, JD Doctor Profile & Reviews | University Hospitals - May 9th, 2023
- Peripheral Neuropathy: What It Is, Symptoms & Treatment - Cleveland Clinic - May 1st, 2023
- Peripheral Neuropathy | National Institute of Neurological Disorders ... - May 1st, 2023
- Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study... - May 1st, 2023
- Successfully Treating Diabetic Neuropathy at Vero Neuropathy | Paid Content - Local 5 - weareiowa.com - May 1st, 2023
- Peripheral Neuropathy Treatment at Advanced Nerve and Health Center - WFAA.com - May 1st, 2023
- Different Types of Peripheral Neuropathy | Paid Content - Local 5 - weareiowa.com - February 24th, 2023
- Peripheral neuropathy: Symptoms, causes, and treatment - Medical News Today - February 24th, 2023
- Natural Treatments for Peripheral Neuropathy - Healthline - December 28th, 2022
- Diabetic neuropathy types: Symptoms tell the story - Mayo Clinic - December 28th, 2022
- Supplements for Neuropathy: Vitamins and More - Healthline - December 28th, 2022
- The Effectiveness of Topical Cannabidiol Oil in Symptomatic ... - PubMed - December 28th, 2022
- Autonomic neuropathy - Diagnosis and treatment - Mayo Clinic - December 28th, 2022
- Peripheral neuropathy - Causes - NHS - December 28th, 2022
- Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and ... - PubMed - December 28th, 2022
- What Is Auditory Neuropathy? Causes & Treatment | NIDCD - December 20th, 2022
- Vero Neuropathy and Their Patients Pain Free Success Stories | Paid Content - Local 5 - weareiowa.com - December 20th, 2022
- Neuropathy No More Reviews (Blue Heron Health News) Does It Work? - Outlook India - December 20th, 2022
- Neuropathy Pain Treatment Market Size to Grow by USD 3.81 Bn, Growing Focus on Emerging Economies to be a Key Trend - Technavio - Yahoo Finance - October 7th, 2022
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 7th, 2022
- Anti-hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin-induced diabetic neuropathy imply MAPK pathway and calcium dynamics... - October 7th, 2022
- Side effects that may arise during breast cancer treatment The Hamburg Reporter - Hamburg Reporter - October 7th, 2022
- Neuropathy & the Truth About Alternative Care - North Forty News - June 16th, 2022
- Thermal gradient ring reveals thermosensory changes in diabetic peripheral neuropathy in mice | Scientific Reports - Nature.com - June 16th, 2022
- GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022 - Business Wire - June 16th, 2022
- Warning Signs of Diabetes, Says Physician Eat This Not That - Eat This, Not That - June 16th, 2022
- Foot Disease: The Most Feared Of All The Consequences Of Diabetes - Pressat - June 16th, 2022
- How Mindfulness Meditation May Help Ease Stress and Anxiety in Cancer Survivors, and Where to Start - Curetoday.com - June 16th, 2022
- TYPES OF CANNABIS STRAINS AND THE TYPE OF PAIN THEY TREAT - GISuser.com - June 16th, 2022
- 5 Types of Neuropathy and What to Do About Them | Fort ... - April 26th, 2022
- Unilateral Compressive Optic Neuropathy As the Presenting Manifestation of Clival Chordoma: A Case Report - Cureus - April 26th, 2022
- A Case of Secondary Trigeminal Neuropathy Due to Local Malignant Invasion of the Maxillary and Mandibular Nerves at the Skull Base: A Case Report With... - April 26th, 2022
- Global Leber's Hereditary Optic Neuropathy Drug Market 2022 to 2031 Analysis themobility.club - themobility.club - April 26th, 2022
- Risks of vitamin B12 deficiency and the symptoms to look out for - My London - April 26th, 2022
- NeuraLace announces two new patents for Axon neuropathic pain therapies - NeuroNews International - April 26th, 2022
- Neuropathic pain Market Overview By Share, Size, Industry Players, Revenue and Product Demand 2021-2030 The New York Irish Emgirant - The New York... - April 26th, 2022
- Find Help For Peripheral Neuropathy With Corrective Health - KXAN.com - November 21st, 2021
- AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022 - Business Wire - November 21st, 2021
- Diabetic Neuropathy Treatment Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Northwest Diamond Notes - November 21st, 2021
- Diabetes: The 'tingling' sensation that can be caused by long-term high blood sugar - Daily Express - November 21st, 2021
- Vaccinations urged against shingles, a viral infection that's on the rise - Yahoo News - November 21st, 2021
- Broadway Vascular Announces Top-Line Results of 12-Month Retrospective Analysis Evaluating Revascularization of the Lateral Plantar Artery in Diabetic... - October 26th, 2021
- Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency - Yahoo Finance - October 26th, 2021
- Heres Why Alger Sold its Nevro Corp. (NVRO) Position - Yahoo Finance - October 26th, 2021
- Zika virus in UP: Symptoms, treatment and other things to know - Hindustan Times - October 26th, 2021
- Ask the GP: Why do my feet feel like they're on fire? - The Irish News - October 26th, 2021
- For veterans: VA prepares to tackle backlogged disability claims - The Herald-Times - October 26th, 2021
- Tri-State Neuropathy Centers continues to expand its peripheral neuropathy treatment practice in the tri-state area to continue its mission to help... - August 17th, 2021
- Out of Every Ten Diabetic Patient, At least Seven are Identified with Diabetic Neuropathy - BioSpace - August 17th, 2021
- CCM can identify nerve damage in patients with long COVID, new study finds - Mobihealth News - August 17th, 2021
- Spotlight on ultrasonography in the diagnosis of PND | IJGM - Dove Medical Press - August 17th, 2021
- Eye scan could determine whether COVID patients will be long haulers - WGNO New Orleans - August 17th, 2021
- Diabetic Neuropathy Treatment Market Trends and Forecast to 2027 Players are Abbott, Roche, Eli Lilly - The Manomet Current - August 17th, 2021
- The Feather and the Knife: Navigating Life With Chronic Pain - POZ - August 17th, 2021
- Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing - Yahoo Finance - August 17th, 2021
- Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Yahoo Finance - August 17th, 2021
- Ugly Side Effects of Too Many Vitamins - Eat This Not That - Eat This, Not That - August 17th, 2021
- Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years in the Domain - Digital... - May 14th, 2021
- Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy - BioSpace - May 14th, 2021
- Global Chronic Pain associated with Painful Diabetic Neuropathy Market to 2025 - Insight, Competitive Landscape and Forecasts - ResearchAndMarkets.com... - May 14th, 2021
- Leber's Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Will Accelerate at a CAGR Through 2021-2027 | Rising Technological Innovations... - May 14th, 2021
- Chemotherapy induced peripheral neuropathy Pipeline Insight to See Strong Expansion Through 2027 Covid-19 Analysis The Courier - The Courier - May 14th, 2021
- Diabetic Retinopathy Market Size Growth Expects Significant Thrust at a CAGR of 3% During the Study Period, 2018-30 in the 7MM | DelveInsight -... - May 14th, 2021
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19 - Business Wire - May 14th, 2021
- Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2... - May 14th, 2021
- Phenotypic Stratification of Patients With Painful Neuropathy May Predict Response to Therapy - Clinical Pain Advisor - May 2nd, 2021
- Peripheral Neuropathy Treatment Market: Development, Growth, Trends, Demand, Analysis and Forecast 2026 KSU | The Sentinel Newspaper - KSU | The... - May 2nd, 2021
- Diabetic Neuropathy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 The Courier - The Courier - May 2nd, 2021
- Leber's Hereditary Optic Neuropathy Drug Market Size and Forecast 2027 | Top Key Players Alkeus Pharmaceuticals, Ixchel Pharma, LLC, Biovista Inc.,... - May 2nd, 2021
- There are treatment options for neuropathy | News, Sports, Jobs - SalemNews.net - March 3rd, 2021
- Global Optic Neuropathy Drug Market: Industry Analysis and Forecast (2021-2028) By Products, Application, End-uses, and Region. KSU | The Sentinel... - March 3rd, 2021